Vilin Bio Med Ltd IPO Timeline

Vilin Bio Med Ltd IPO opens on 16-Jun-2023, and closes on 21-Jun-2023. The Vilin Bio Med Ltd IPO bid date is from 16-Jun-2023 to 21-Jun-2023. The Cut-off time for UPI Mandate confirmation is 12 P.M. on the next day of issue closing day.

Event Date
Vilin Bio Med Ltd IPO Opening Date 16-Jun-2023
Vilin Bio Med Ltd IPO Closing Date 21-Jun-2023
Basis of Allotment 26-Jun-2023
Initiation of Refunds 27-Jun-2023
Credit of Shares to Demat 29-Jun-2023
Vilin Bio Med Ltd IPO Listing Date 30-Jun-2023

Vilin Bio Med Ltd IPO Lot Size

Vilin Bio Med Ltd IPO lot size is 4000 shares. A retail-individual investor can apply for up to 1 lots (4000 shares or 120000).

Application Lots Shares Amount
Minimum 1 4000 ₹120000
Maximum 1 4000 ₹120000

Vilin Bio Med Ltd IPO Details

Vilin Bio Med Ltd IPO Date 16-Jun-2023 to 21-Jun-2023
Vilin Bio Med Ltd IPO Face Value Shares of ₹10 per share
Vilin Bio Med Ltd IPO Price ₹30 per share
Vilin Bio Med Ltd IPO Lot Size 4000
Issue Size Shares of ₹10 (aggregating up to ₹12 Cr)
Fresh Issue Shares of ₹10 (aggregating up to ₹12 Cr)
Offer for Sale -
Issue Type Fixed Price - SME
Listing At NSE - SME
QIB Shares Offered -
Retail Shares Offered -
NII (HNI) Shares Offered -
Company Promoters Viswa Prasad Sadhanala, Sadhanala Venkata Rao, D Srinivasa Reddy.

Objects of the Issue

The company proposes to utilise the Net Proceeds from the Fresh Issue towards funding the following objects:

  • 1 Augmenting additional working capital requirements
  • 2 General Corporare Purposes

Company Financials

Vilin Bio Med Ltd Financial Information (Restated)

Period Ended Total Assets Total Revenue Profit After Tax
03-2023 17.68 12.34 1.24
03-2022 13.56 11.22 0.03
03-2021 13.89 11.72 0.12
Amount in ₹ Crore
  • Experienced Management and Dedicated Employee Base.
  • Quality Assurance.
  • There are certain outstanding legal proceeding against the company which may adversely affect its business, financial condition and results of operations.
  • There are outstanding criminal legal proceedings involving the Company which may adversely affect its business, financial condition and results of operations.
  • There were certain NCLT cases that have been filed against the Company in the past.
  • The company conduct its business activities on a purchase order basis and therefore have not entered into long-term agreements with its customers.
  • The Company is reliant on the demand from the pharmaceutical industry for a significant portion of its revenue. Any downturn in the pharmaceutical industry or an inability to increase or effectively manage its sales could have an adverse impact on the Company's business and results of operations.
  • The company highly depend on its major raw materials and a few key suppliers who help its procure the same. The Company has not entered into long-term agreements with its suppliers for supply of raw materials. In the event its unable to procure adequate amounts of raw materials, at competitive prices its business, results of operations and financial condition may be adversely affected.
  • The company continued operations are critical to its business and any shutdown of its manufacturing unit may adversely affect the company business, results of operations and financial condition.
  • Any failure in its quality control processes may adversely affect the company business, results of operations and financial condition. Its may face product liability claims and legal proceedings if the quality of its products does not meet the company customers' expectations.
  • Any adverse change in regulations governing its products and the products of the company customers, may adversely impact its business prospects and results of operations.
  • Any delays and/or defaults in customer payments could result in increase of working capital investment and/or reduction of the Company's profits, thereby affecting its operation and financial condition.
  • The Company requires significant amount of working capital for a continuing growth. Its inability to meet its working capital requirements may adversely affect the company results of operations.
  • The company are 100% dependent on third party transportation providers for delivery of raw materials to its from the company suppliers and delivery of the company products to its customers. The company has not entered into any formal contracts with its transport providers and any failure on part of such service providers to meet their obligations could adversely affect its business, financial condition and results of operation.
  • The company inability to manage inventory in an effective manner could affect its business.
  • If the Company is unable to protect its intellectual property, or if the Company infringes on the intellectual property rights of others, its business may be adversely affected.
  • The company has historically derived, and may continue to derive, a significant portion of its income from the company top 10 customers.
  • The company operate in a competitive business environment and its inability to compete effectively may adversely affect the company business, results of operations, financial condition and cash flows.
  • The company Audit Report for FY 2020 includes following remarks by Statutory Auditor w.r.t. the CARO for default on payment of Statutory Dues.
  • There have been delays in GST returns and EPF payments by the Company.
  • One of the Group Company, Pharmaids Pharmaceuticals Limited was declared as "Wilful Defaulter".
  • The company might face claims / liabilities / suits from its customers should they perceive any deficiency in service or in the event of bodily harm / injury to them during its events organized by the company.
  • The company Promoters, Directors and Key Managerial Personnel have interests in the Company other than reimbursement of expenses incurred or normal remuneration or benefits.
  • The company Promoters and members of the Promoter Group have significant control over the Company and have the ability to direct its business and affairs; their interests may conflict with its interests as a shareholder.
  • The average cost of acquisition of Equity Shares held by its Promoters could be lower than the Issue Price.
  • The company has in the past entered into related party transactions and may continue to do so in the future, which may potentially involve conflicts of interest with the equity shareholders.
  • Increased losses due to fraud, employee negligence, theft or similar incidents may have an adverse impact on it.
  • The company agreements with lenders for financial arrangements contain restrictive covenants for certain activities and if its unable to get their approval, it might restrict the company scope of activities and impede its growth plans.
  • The company business requires it to obtain and renew certain registrations, licenses and permits from government and regulatory authorities and the failure to obtain and renew them in a timely manner may adversely affect its business operations.
  • Operational risks are inherent in its business as it includes rendering services at high quality standards. A failure to manage such risks could have an adverse impact on its business, results of operations and financial condition.
  • The Company has availed certain unsecured loans from the Promoters and Promoter Group that are recallable by the lenders at any time.
  • The company has referred to the data derived from internal Company reports and industry and government publications, publicly available information, and sources.
  • The company success depends largely upon the services of its Promoters, Managing Directors and other key managerial personnel and its ability to attract and retain them.
  • The company inability to manage growth could disrupt its business and reduce the company profitability.
  • The company has not made any alternate arrangements for meeting its capital requirements for the Objects of the issue. Further its have not identified any alternate source of financing the 'objects of the Issue'. Any shortfall in raising / meeting the same could adversely affect its growth plans, operations, and financial performance.
  • The objects of the Issue include funding working capital requirements of the Company, which are based on certain assumptions and estimates and such working capital requirements may not be indicative of the actual requirements of the Company. Additionally, its financing requirements and the deployment of the net proceeds of the Issue are based on management estimates and have not been independently appraised.
  • Operating Expenses constitute a significant percentage of the Company's total expenses. Any increase in prices and any decrease in the supply would materially adversely affect the Company's business.
  • Any failure to keep abreast with the latest trends in the technologies may adversely affect its cost competitiveness and ability to develop new products.
  • The business which we undertake may be delayed, modified, cancelled, or not fully paid for by its clients and therefore, could materially affect the company business, results of operations and financial condition.
  • The company do not own its registred office from which we operate.
  • The company results of operations are likely to vary from year to year and be unpredictable, which could cause the market price of the Equity Shares to be volatile.
  • Any variation in the utilization of the Net Proceeds as disclosed in this Prospectus shall be subject to certain compliance requirements, including prior Shareholders' approval.
  • The company funding requirements and deployment of the issue proceeds are based on management estimates and have not been independently appraised by any bank or financial institution.
  • The Company's management will have flexibility in utilizing the Net Proceeds. There is no monitoring agency appointed by the Company and the deployment of funds is at the discretion of its Management and its Board of Directors, though it shall be monitored by the company Audit Committee.
  • The company has experienced negative cash flows in the past. Any such negative cash flows in the future could adversely affect its business, results of operations and prospects.
  • The company has not made any dividend payments in the past and its ability to pay dividends in the future will depend upon future earnings, financial condition, cash flows, working capital requirements, capital expenditures and restrictive covenants in its financing arrangements.
  • The requirements of being a listed company may strain its resources.
  • Improve Production Capacity.
  • Continue to focus on Operational Efficiency.
  • Enhancing Customer Base.

Vilin Bio Med Ltd IPO Promoter Holding

Pre Issue Share Holding 89.88%
Post Issue Share Holding 64.10%

Vilin Bio Med Ltd IPO Subscription Status (Bidding Detail)

The Vilin Bio Med Ltd IPO is subscribed - times on Jun 21, 2023 05:00:00 PM. The public issue subscribed - times in the retail category, - times in the QIB category, and - times in the NII category. Check Day by Day Subscription Details (Live Status)

Category QIB NII Retail Employee Total
Subscription (times) - - - - -

Vilin Bio Med Ltd IPO Prospectus

Vilin Bio Med Ltd IPO Listing Date

Listing Date 30 Jun 23
BSE Script 78871
NSE Symbol VILINBIO
Listing In NSE - SME
ISIN INE0L4V01013
IPO Price ₹30
Face Value ₹10

Vilin Bio Med Ltd IPO Registrar

Bigshare Services Pvt Ltd

Phone: +91 22 6263 8200
Email: ipo@bigshareonline.com
Website: www.bigshareonline.com

Vilin Bio Med Ltd IPO Lead Manager(s)

  1. Inventure Merchant Banker Services Pvt Ltd

FAQs on Vilin Bio Med Ltd IPO

Vilin Bio Med Ltd IPO, which opens for subscription from 16-Jun-2023 to 21-Jun-2023 has an issue size of ₹12 crore. The issue type is book building issue.

In case of pre-apply, your IPO order will be placed on the Exchange as soon as the official bidding for Vilin Bio Med Ltd IPO begins. You will receive a UPI request within 24 hours after the bidding period opens.

Vilin Bio Med Ltd IPO Opens for subscription from 16-Jun-2023 to 21-Jun-2023.

The lot size of Vilin Bio Med Ltd is 4000 shares. Retail investors can subscribe to minimum 1 lot and maximum 1 lots. The minimum and maximum application value is ₹120000 and ₹120000 respectively.

Allotment date for Vilin Bio Med Ltd is 26-Jun-2023 and refund of application amount (in case allotment is not received) will begin from 27-Jun-2023. If your allotment goes through, then shares will be credited in your Demat account by 29-Jun-2023.

The registrar for Vilin Bio Med Ltd IPO is Bigshare Services Pvt Ltd . You can check your IPO allotment status on the registrar's website.

The shares of Vilin Bio Med Ltd are proposed to be listed on Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).

Power your investments with our smart trading platforms

mobilefooterimg
  • app_download_icon_img
    5 million+
    App downloads
  • 1_Click_icon_img
    1-Click
    Order Placement
  • higherreturns_icon_img
    2,361 Crore+
    Average Daily Turnover
Download App